(September 26, 2016, 1:16 PM EDT) -- ALEXANDRIA, Va. — A petition by Teva Pharmaceuticals USA Inc. for inter partes review of 31 claims of a patent that claims compositions useful in the treatment of diabetes was granted Sept. 23 by the Patent Trial and Appeal Board, which additionally agreed that the challenge should be consolidated with an IPR petition by Mylan Pharmaceuticals Inc. that was granted in May (Teva Pharmaceuticals USA Inc. v. Astrazeneca AB, No. IPR2016-01122, PTAB).

(Decision available. Document #16-161003-014Z.)

According to the board, Teva and Mylan have demonstrated that...